


RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

09/831,253C

Source:

1600

Date Processed by STIC:

10/9/2003

RECEIVED

OCT 21 2003

TECH CENTER 10002300

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER
VERSION 4.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkr41note.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/efb/efs/downloads/documents.htm>), EFS Submission User Manual (ePAVE)

2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

3. Hand Carry directly to (EFFECTIVE 12/01/2003):

U.S. Patent and Trademark Office, Box Sequence, Customer Window/Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 10/08/2003

Raw Sequence Listing Error Summary

<u>ERROR DETECTED</u>	<u>SUGGESTED CORRECTION</u>	SERIAL NUMBER: <u>09/831,253C</u>
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE		
1 <input type="checkbox"/> Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."	
2 <input type="checkbox"/> Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.	
3 <input checked="" type="checkbox"/> Misaligned Amino Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.	
4 <input type="checkbox"/> Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.	
5 <input type="checkbox"/> Variable Length	Sequence(s) _____ contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.	
6 <input type="checkbox"/> PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
7 <input type="checkbox"/> Skipped Sequences (OLD RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.	
8 <input checked="" type="checkbox"/> Skipped Sequences (NEW RULES)	Sequence(s) <u>166</u> missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000	
9 <input type="checkbox"/> Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
10 <input type="checkbox"/> Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence	
11 <input type="checkbox"/> Use of <220>	Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 07/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)	
12 <input type="checkbox"/> PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	
13 <input type="checkbox"/> Misuse of n/Xaa	"n" can only represent a single <u>nucleotide</u> ; "Xaa" can only represent a single <u>amino acid</u>	



1600

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/831,253C

DATE: 10/07/2003
TIME: 10:20:47

Input Set : A:\0134469 sequence listing .txt
Output Set: N:\CRF4\10072003\I831253C.raw

Suggestion: PLEASE
Consult
Sequence
Rules
for
Does Not Comply
Corrected Diskette Needed
VALID

1 <110> APPLICANT: EZQUERRO SAENZ, Ignacio Jose
2 LASARTE SAGASTIBELZA, Juan Jose
3 PRIETO VALTUEYA, Jesus
4 BORRAS CUESTA, Francisco
6 <120> TITLE OF INVENTION: TGFbb1-inhibitor peptides
8 <130> FILE REFERENCE: U-013446-9
10 <140> CURRENT APPLICATION NUMBER: 09/831,253C
11 <141> CURRENT FILING DATE: 2001-06-27
13 <150> PRIOR APPLICATION NUMBER: PCT/ES99/00375
14 <151> PRIOR FILING DATE: 1999-11-23
16 <150> PRIOR APPLICATION NUMBER: P9802465
17 <151> PRIOR FILING DATE: 1998-11-24
E--> 19 <160> NUMBER OF SEQ ID NOS: 160 179

IMPORTANT: see p.3
(total number
of sequences
is 178)

submitted
file showed >160/179. Please correct.

ERRORED SEQUENCES

do NOT use alphabetical headings
In new Sequence Rules
format. CRF software inserts
alphabetical headings.

E--> 22 <210> SEQ ID NO: ~~SEQ ID NO: 1~~
23 <211> LENGTH: 15 *delete*
E--> 24 <212> TYPE: ~~Peptide~~ *PRT*
25 <213> ORGANISM: Artificial sequence
W--> 26 <220> ~~FEATURE: Domain~~ *NEVER insert a response to <220>.*
W--> 26 <220> ~~FEATURE: Domain~~ *insert <221> and have response to <221> line.*
27 <223> OTHER INFORMATION: Derived from human TGBb1 position 319-333
W--> 28 <400> ~~SEQUENCE:~~ *His Ala Asn Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu*
29 *4007 1* *5 10 10 15*
E--> 32 <210> SEQ ID NO: ~~SEQ ID NO: 2~~
33 <211> LENGTH: 14 *delete*
E--> 34 <212> TYPE: ~~Peptide~~ *PRT* *misaligned nos. see item 3 on ENOV*
35 <213> ORGANISM: Artificial sequence *summary sheet*
W--> 36 <220> ~~FEATURE: Domain~~
W--> 36 <220> ~~FEATURE: Domain~~ *<221>*
37 <223> OTHER INFORMATION: Derived from human TGBb1 position 322-335
W--> 38 <400> ~~SEQUENCE:~~ *Phe Cys Leu Gly Pro Cys Pro Tyr Ile Trp Ser Leu Asp Thr*
39 *4007 2* *5 5 10 10*
E--> 43 <210> SEQ ID NO: ~~SEQ ID NO: 3~~
44 <211> LENGTH: 12
E--> 45 <212> TYPE: ~~Peptide~~
46 <213> ORGANISM: Artificial sequence
W--> 47 <220> ~~FEATURE: Domain~~
W--> 47 <220> ~~FEATURE: Domain~~ *<221>*
48 <223> OTHER INFORMATION: Derived from rat TGBb1 type III receptor position 731-742
W--> 49 <400> ~~SEQUENCE:~~ *Thr Ser Leu Asp Ala Thr Met Ile Trp Thr Met Met*
4007 3 *5 10*

Replace with <160>
do not insert this on <400> line.
Move this under <400> line.
move under <400> line

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/831,253C

DATE: 10/07/2003

TIME: 10:20:47

Input Set : A:\0134469 sequence listing .txt

Output Set: N:\CRF4\10072003\I831253C.raw

50
E--> 53 <210> SEQ ID NO: SEQ ID NO: 4
54 <211> LENGTH: 15
E--> 55 <212> TYPE: Peptide
56 <213> ORGANISM: Artificial sequence
W--> 57 <220> FEATURE: Domain
W--> 57 <220> FEATURE: Domain
58 <223> OTHER INFORMATION: Derived from rat TGBb1 position 245-259
W--> 59 <400> SEQUENCE: Ser Asn Pro Tyr Ser Ala Phe Gln Val Asp Ile Ile Val Asp Ile
60 5 10 15
E--> 63 <210> SEQ ID NO: SEQ ID NO: 5
64 <211> LENGTH: 9
E--> 65 <212> TYPE: Peptide
66 <213> ORGANISM: Synthetic peptide derived from P54
W--> 67 <220> FEATURE: Domain
W--> 67 <220> FEATURE: Domain
W--> 68 <400> SEQUENCE: Thr Ser Leu Met Ile Trp Thr Met Met
69 5
E--> 72 <210> SEQ ID NO: SEQ ID NO: 6
73 <211> LENGTH: 14
E--> 74 <212> TYPE: Peptide
75 <213> ORGANISM: Synthetic peptide from human TGBb1 type III receptor
W--> 76 <220> FEATURE: Domain: 729-742
W--> 76 <220> FEATURE: Domain: 729-742
W--> 77 <400> SEQUENCE: Thr Ser Leu Asp Ala Ser Ile Ile Trp Ala Met Met Gln Asn
78 5 10
E--> 81 <210> SEQ ID NO: SEQ ID NO: 7
82 <211> LENGTH: 14
E--> 83 <212> TYPE: Peptide
84 <213> ORGANISM: Synthetic peptide from human TGBb1 type III receptor
W--> 85 <220> FEATURE: Domain: 241-254
W--> 85 <220> FEATURE: Domain: 241-254
W--> 86 <400> SEQUENCE: Ser Asn Pro Tyr Ser Ala Phe Gln Val Asp Ile Thr Ile Asp
87 5 10
E--> 90 <210> SEQ ID NO: SEQ ID NO: 8
91 <211> LENGTH: 15
E--> 92 <212> TYPE: Peptide
93 <213> ORGANISM: Synthetic peptide from pig endoglin
W--> 94 <220> FEATURE: Domain: 247-261
W--> 94 <220> FEATURE: Domain: 247-261
W--> 95 <400> SEQUENCE: Glu Ala Val Leu Ile Leu Gln Gly Pro Pro Tyr Val Ser Trp Leu
96 5 10 15
E--> 99 <210> SEQ ID NO: SEQ ID NO: 9
100 <211> LENGTH: 15
E--> 101 <212> TYPE: Peptide
102 <213> ORGANISM: Synthetic peptide from pig endoglin
W--> 103 <220> FEATURE: Domain: 445-459
W--> 103 <220> FEATURE: Domain: 445-459
W--> 104 <400> SEQUENCE: Leu Asp Ser Leu Ser Phe Gln Leu Gly Leu Tyr Leu Ser Pro His

09/83/25x 3

<210> SEQ ID NO: 132

<211> 15

<212> Peptide

<213> Synthetic peptide from rat TGBb1 type III receptor

<220> Domain: 350-364

<223> ~~Description/Position~~ delete

<400> Val Ala Asn Arg Phe His Leu Arg Leu Glu Asn Asn Glu Glu Met
5 10 15

09/83/ 253C 4

<210> SEQ ID NO: 165

<211> 12

<212> Peptide

<213> Synthetic peptide from human alpha 2 microglobulin

<220> Domain: 554-565

<400> Asp Ser Ala Lys Tyr Asp Val Glu Asn Cys Leu Ala

sequence 166 ⁵ missing. If ¹⁰intentionally skipped, please use
format shown
in item 8 of
Error Summary
sheet

<210> SEQ ID NO: 167

The types of errors shown exist throughout
the Sequence Listing. Please check all
sequences for similar errors.

Every sequence in submitted file is
errored.

Please consult sample Sequence Listing
(attached)

```

<110>      Smith, John; Smithgene Inc.

<120>      Example of a Sequence Listing

<130>      01-00001

<140>      PCT/EP98/00001
<141>      1998-12-31

<150>      US 08/999,999
<151>      1997-10-15

<160>      6

<170>      PatentIn version 2.0

<210>      1
<211>      389
<212>      DNA
<213>      Paramecium sp.

<220>
<221>      CDS
<222>      (279)...(389)

<300>
<301>      Doe, Richard
<302>      Isolation and Characterization of a Gene Encoding a
              Protease from Paramecium sp.
              Journal of Genes
<303>
<304>      1
<305>      4
<306>      1-7
<307>      1988-06-31
<308>      123456
<309>      1988-06-31

<400>      1
agctgtagtc attcctgtgt cctctctctt ctgggcttct caccctgcta atcagatctc      60
agggagagtg tcttgacctt cctctgcctt tgcagcttca caggcaggca ggcaggcagc      E 120
tgaatgtgga atcgtctgga gtgccacagg ctcttcagcc aggccttaggg tgggttcggc      180
cgcggcgagg cggccctctt cgcgtctctc tcgcgcctct ctctcgtctt cctctcgtct      240

```

Consult this

Appendix 3, page 2.

```

ggacctgatt  aggtcagcag  gagggaggggg  cagtttagc      atg  gtt  tca  atg  ttc  agc  296
Met  Val  Ser  Met  Phe  Ser

ttg  tct  ttc  aaa  tgg  cct  gga  ttt  tgt  ttg  ttt  gtt  tgt  ttg  ttc  caa  344
Leu  Ser  Phe  Lys  Trp  Pro  Gly  Phe  Cys  Leu  Phe  Val  Cys  Leu  Phe  Gln

tgt  ccc  aaa  gtc  ctc  ccc  tgt  cac  tca  tca  ctg  cag  ccg  aat  ctt  389
Cys  Pro  Lys  Val  Leu  Pro  Cys  His  Ser  Ser  Leu  Gln  Pro  Asn  Leu

<210>      2
<211>      37
<212>      PRT
<213>      Paramesium sp.

<<400>      2
Met  Val  Ser  Met  Phe  Ser  Leu  Ser  Phe  Lys  Trp  Pro  Gly  Phe  Cys  Leu
1      5      10

Phe  Val  Cys  Leu  Phe  Gln  Cys  Pro  Lys  Val  Leu  Pro  Cys  His  Ser  Ser
20      25      30

Leu  Gln  Pro  Asn  Leu
35

<210>      3
<211>      11
<212>      PRT
<213>      Artificial Sequence

<220>
<221>      Designed peptide based on size and polarity to act as a
linker between the alpha and beta chains of Protein XYZ.

<400>      3
Met  Val  Asn  Leu  Glu  Pro  Met  His  Thr  Glu  Ile
1      5      10

<210>      4
<400>      4
000

```

[Annex VIII follows]